The therapy of congenital myasthenic syndromes-Reference-Cited by-同舟云学术

The therapy of congenital myasthenic syndromes

Published:2007-04 Issue:2 Volume:4 Page:252-257
ISSN:1933-7213
Container-title:Neurotherapeutics
language:en
Short-container-title:Neurotherapeutics

Author:

Engel Andrew G.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Clinical Neurology,Pharmacology

Link

http://www.springerlink.com/index/pdf/10.1016/j.nurt.2007.01.001

Reference46 articles.

1. Salpeter MM. Vertebrate neuromuscular junctions: general morphology, molecular organization, and functional consequences. In: Salpeter MM, ed. The vertebrate neuromuscular junction. New York: Wiley; 1987: 1–54.

2. Flucher BE, Daniels MP. Distribution of Na+ channels and ankyrin in neuromuscular junctions is complementary to that of acetylcholine receptors and the 43 kd protein. Neuron 1989;3: 163–175.

3. Ruff RL. Sodium channel slow inactivation and the distribution of sodium channels on skeletal muscle fibres enable the performance properties of different skeletal muscle fiber types. Acta Physiol Scand 1996;156: 159–168.

4. Martin AR. Amplification of neuromuscular transmission by postjunctional folds. Proc R Soc Lond B Biol Sci 1994;258: 321–326.

5. Wood SJ, Slater CP. Safety factor at the neuromuscular junction. Prog Neurobiol 2001;64: 393–429.

Cited by 94 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Congenital Myasthenic Syndromes in Belgium: Genetic and Clinical Characterization of Pediatric and Adult Patients;Pediatric Neurology;2024-09

2. Rare disease research workflow using multilayer networks elucidates the molecular determinants of severity in Congenital Myasthenic Syndromes;Nature Communications;2024-02-28

3. Neuromuscular and Neuromuscular Junction Manifestations of the PURA-NDD: A Systematic Review of the Reported Symptoms and Potential Treatment Options;International Journal of Molecular Sciences;2023-01-23

4. Rare disease research workflow using multilayer networks elucidates the molecular determinants of severity in Congenital Myasthenic Syndromes;2023-01-20

5. Congenital Myasthenic Syndromes in Turkey: Clinical and Molecular Characterization of 16 Cases With Three Novel Mutations;Pediatric Neurology;2022-11